Tecfidera trial to slow worsening geographic atrophy
Treatments studied
Part of Eyes & vision clinical trials.
This Phase 2 study tests dimethyl fumarate (Tecfidera) to slow the growth of geographic atrophy, a form of age-related macular degeneration that affects central vision. You may be asked to take the study medicine and attend regular eye scans over about 2 years to see if it helps.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 55 and 85 years old when you start the study
- You have geographic atrophy in at least one eye, sized within the study’s limits
- Your vision in the affected eye is between 20/20 and 20/200, and your eye images can be taken clearly
- You can understand the consent form and follow the study visits and procedures
- You do not have certain brain MRI findings (for people in the Tecfidera group) soon after starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
This study observes how geographic atrophy (an advanced form of dry age-related macular degeneration) changes over a short period. If you have this condition in both eyes and meet certain vision and eye health criteria, you may be able to join this non-treatment study to help researchers learn more about the disease.
This study tests a new medicine (ABBV-6628) given as an injection into the eye to see how well it works and how it moves through the body for people with geographic atrophy (an advanced form of dry age-related macular degeneration). It may help slow vision loss from this condition.
This trial tests an investigational drug FWY003 against a placebo to see if it can slow or stop the progression of geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss.
This study tests a new drug called STL303 for geographic atrophy, a condition where the back of the eye slowly loses cells, causing vision loss. The drug aims to slow or stop this vision loss in people over 60.
This trial is testing a new treatment called CTx001 for people with geographic atrophy (GA), a late stage of dry age-related macular degeneration (AMD). The goal is to see if the treatment is safe and can slow vision loss.
Hear when a new Age-related Macular Degeneration (AMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.